These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 8811491)

  • 21. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy.
    Katz A; Shulman LM; Porgador A; Revel M; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):98-109. PubMed ID: 8318501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA.
    Rosendahl A; Kristensson K; Carlsson M; Skartved NJ; Riesbeck K; Søgaard M; Dohlsten M
    Int J Cancer; 1999 Mar; 81(1):156-63. PubMed ID: 10077167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.
    Palomares T; Bilbao P; Alonso-Varona A; Barberá-Guillem E
    Cancer Immunol Immunother; 1995 May; 40(5):292-8. PubMed ID: 7600560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.
    Chavin KD; Qin L; Lin J; Woodward JE; Baliga P; Bromberg JS
    Ann Surg; 1993 Oct; 218(4):492-501; discussion 501-3. PubMed ID: 8215640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
    Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
    Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
    Geehan DM; Fabian DF; Lefor AT
    J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type-1 transforming growth factor-beta differentially modulates tumoricidal activity of murine peritoneal macrophages against metastatic variants of the B16 murine melanoma.
    Fan D; Liaw A; Denkins YM; Collins JH; Van Arsdall M; Chang JL; Chakrabarty S; Nguyen D; Kruzel E; Fidler IJ
    J Exp Ther Oncol; 2002; 2(5):286-97. PubMed ID: 12416032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
    Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
    Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
    Seo N; Tokura Y; Takigawa M; Egawa K
    J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-beta inhibits interleukin-12-induced production of interferon-gamma by natural killer cells: a role for transforming growth factor-beta in the regulation of T cell-independent resistance to Toxoplasma gondii.
    Hunter CA; Bermudez L; Beernink H; Waegell W; Remington JS
    Eur J Immunol; 1995 Apr; 25(4):994-1000. PubMed ID: 7737303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
    Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
    Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    J Cell Biochem; 2006 Apr; 97(5):1036-51. PubMed ID: 16294321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental approaches for the treatment of murine B16 melanomas of various sizes. I: Local injection of ethanol with a combination of interleukin-2 or microwaval hyperthermia for B16 melanomas with a size of less than 7 mm in diameter.
    Nakayama J; Kokuba H; Kobayashi J; Yoshida Y; Hori Y
    J Dermatol Sci; 1997 Aug; 15(2):75-81. PubMed ID: 9279687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
    Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
    Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-beta.
    Nelson BJ; Danielpour D; Rossio JL; Turpin J; Nacy CA
    J Leukoc Biol; 1994 Jan; 55(1):81-90. PubMed ID: 8283143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-stimulation of T cell proliferation by transforming growth factor-beta 1.
    Lee HM; Rich S
    J Immunol; 1991 Aug; 147(4):1127-33. PubMed ID: 1831218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.